International Stem Cell Corporation
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andrey Semechkin
- Full Time Employees
- 32
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9745 Businesspark Avenue San Diego CA United States of America 92131
- IPO Date
- May 1, 2007
- CIK
- 0001355790
- Website
- internationalstemcell.com
- Similar Companies
- Business
- International Stem Cell Corporation International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology company that develops human parthenogenetic stem cell (hpSC) technologies for regenerative medicine applications, including therapeutic neural stem cells, research-grade cell products, and stem cell-based cosmetics. The company offers ISC-hpNSC, a clinical-grade neural stem cell product derived from hpSCs for treating Parkinson's disease, stroke, traumatic brain injury, and Alzheimer's disease; specialized human cell culture products and growth media through subsidiary Lifeline Cell Technology, such as skin cells for dermatology research, cardiovascular cells, bronchial/tracheal lines for respiratory studies, and mammary epithelial cells for cancer research; and stem cell-derived skin care products through subsidiary Lifeline Skin Care. ISCO operates in the United States, Asia, and Europe, targeting therapeutic, research, and consumer markets with its UniStemCell bank potential for immune-matched cells across diverse populations. Founded in 2005 and headquartered in San Diego, California, the company maintains wholly owned subsidiaries including Lifeline Cell Technology, Lifeline Skin Care, and Cyto Therapeutics in Australia. In 2024, ISCO reported revenues of $9.09 million, a 17% increase from 2023, with subsidiary operating income rising 29% to $2.39 million and operational loss shrinking 90% to $68,000, while advancing its Phase I trial for ISC-hpNSC in Parkinson's disease with promising interim safety and efficacy data.
International Stem Cell (OTCMKTS:ISCO) Shares Cross Above 200 Day Moving Average – What’s Next?
International Stem Cell (OTCMKTS:ISCO) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?
International Stem Cell Corp. (OTCMKTS:ISCO) Sees Large Increase in Short Interest
International Stem Cell Corp. (OTCMKTS:ISCO) Sees Large Increase in Short Interest
Short Interest in International Stem Cell Corp. (OTCMKTS:ISCO) Grows By 21.9%
International Stem Cell (OTCMKTS:ISCO) Share Price Crosses Above 200 Day Moving Average – What’s Next?
International Stem Cell (OTCMKTS:ISCO) Stock Passes Above 200-Day Moving Average – Should You Sell?
International Stem Cell Corporation Announces 2024 Fourth Quarter and Year-End Results
Brown-Forman Announces Sale of Cooperage in Alabama
Eighteenth edition of Fujio Cup Quiz won by Kasturba Medical College, India in the NCRM NICHE 2023 international stem cell meeting.